Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral Direct Factor Xa Inhibitor BAY 59-7939 in the Prevention of VTE in Patients Undergoing Total Hip Replacement. ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial

NCT00839826 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00839826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00839826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral Direct Factor Xa Inhibitor BAY 59-7939 in the Prevention of VTE in Patients Undergoing Total Hip Replacement. ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2002
Completion date
November 30, 2003
Enrollment
641 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

prevention, thromboembolism